Adalimumab biosimilar - Meridian BiopharmaceuticalsAlternative Names: MB 612
Latest Information Update: 15 May 2015
At a glance
- Originator Meridian Biopharmaceuticals
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 15 May 2015 Early research in Immunological disorders in Austria (Parenteral)